コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 imator that leverages the shared trial arms (dual therapy).
2 reatment, and 0.49 (0.31-0.79) compared with dual therapy.
3 esting the possibility of using auranofin in dual therapy.
4 r survival rate than those on monotherapy or dual therapy.
5 i-ERBB2 therapy, and they can be targeted by dual therapy.
6 d to achieve high cure rates with vonoprazan dual therapy.
7 reated successfully with only monotherapy or dual therapy.
8 Akkermansia spp. was associated with MPR to dual therapy.
9 , and then robustly upregulated again during dual therapy.
10 ompatible with possible increased risks with dual therapy.
11 ed to enhance the effect of HS-173 gefitinib dual therapy.
12 antibody compromised the survival benefit of dual therapy.
13 udes a protease inhibitor than with standard dual therapy.
14 to continue taking prednisone and tacrolimus dual therapy.
15 y significantly reduced exacerbations versus dual therapies.
17 re randomized 1:1:1 to open-label vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicil
19 infections: vonoprazan triple therapy 65.8%, dual therapy 69.6%, vs lansoprazole triple therapy 31.9%
20 t strains): vonoprazan triple therapy 84.7%, dual therapy 78.5%, vs lansoprazole triple therapy 78.8%
23 trol despite metformin-sulfonylurea (Met-SU) dual therapy, a third-line glucose-lowering medication-i
24 ted with a higher likelihood of SVR than was dual therapy (absolute difference, 22 to 31 percentage p
27 hly active combination therapy or 1 month of dual therapy after SD-NVP prevents most NVP resistance t
28 d TGF-beta1 may provide useful targets for a dual therapy aimed at slowing disease progression in Alp
30 (35 males, 29 females) included: 16 received dual therapies and 16 received triple therapies in TRULI
31 in eight patients (annualised rate 0.6%) on dual therapy and 13 patients (annualised rate 0.9%) on m
35 th T2DM who were free from CVD and on Met-SU dual therapy and who were intensified with DPP4i (n = 8,
36 nical Trial Group (ACTG) 175 (monotherapy vs dual therapy) and ACTG 320 (dual vs triple therapy).
37 3,030 patients) of drugs added to metformin (dual therapy); and 29 trials (10,598 patients) of drugs
39 (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monothera
40 00 person-years of follow-up for patients on dual therapy, and 3.4 per 100 person-years of follow-up
41 tiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy.
42 ten the recommended ceftriaxone-azithromycin dual therapy, and an evidence-based clinical azithromyci
43 -confirmed meningitis and evaluate mono- and dual-therapy antimicrobial regimens for anthrax meningit
45 I 9.93-117) and dolutegravir plus lamivudine dual therapy (aOR 9.21, 2.20-38.6) compared with combina
46 ly better HbA1c lowering in older people for dual therapy (AR, -0.09% [95% CrI, -0.15% to -0.03%] per
47 0.05%] per 30-year increment in age) and for dual therapy (AR, -0.24% [95% CrI, -0.40% to -0.07%]), b
48 to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and
51 serious adverse events occurred, both in the dual-therapy arm, one of which (a case of gastritis) was
53 herapy was effective and non-inferior to HVA dual therapy as first-line treatment of H pylori infecti
55 n of latanoprost and timolol or eligible for dual therapy being not being fully controlled on monothe
57 tential for metformin and estrogen-progestin dual therapy but warrant longitudinal studies examining
58 Lineage tracing reveals that CRC cells evade dual therapy by transitioning into a Paneth-like state.
59 experimental/modeling approach suggest that dual therapy can be more efficacious than single therapi
65 more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of previously untreat
66 with their vascular-modulating function, the dual therapies enhanced morphological normalization of v
68 sult of disease reactivation, whereas 50% of dual-therapy failures were the result of drug intoleranc
70 ndomly assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks
71 sponse rates in HCV-infected women receiving dual therapy for HCV infection, this seems to be less im
72 n that triple therapy is more effective than dual therapy for individuals with uncontrolled asthma.
74 ast 50 copies per mL at 48 weeks between the dual therapy group (three [2%] of 131) and triple therap
75 icular helper cells was also observed in the dual therapy group along the same timeline as an increas
78 ithheld in three (10%) of 30 patients in the dual therapy group due to immune-related adverse events
79 the groups (255 [28%] of 910 patients in the dual therapy group vs 219 [24%] of 921 patients in the m
80 ange in VA for monotherapy compared with the dual therapy group was less than 1 logMAR letter (logMAR
82 group and nine (<1%) of 921 patients in the dual therapy group, was the most common type of bleeding
84 iple-therapy group (n=10 [4.9%]) than in the dual-therapy group (n=1 [0.4%]; difference 4.5%, 95% CI
87 , 217 patients were randomly assigned to the dual-therapy group and 209 to the triple-therapy group.
89 1.4% (95% CI, 31.6 to 78.2; P=0.0013) in the dual-therapy group at day 7 and by 61.6% (95% CI, 34.9 t
90 apy group versus no stroke and 4 TIAs in the dual-therapy group that were treatment emergent and ipsi
92 73 (56%) of 131 participants allocated to dual therapy had 150 adverse effects, compared with 78 (
93 HT, 13/15 (87%) of evaluable participants on dual therapy had no detectable HIV in their genital flui
94 However, the identification of effective dual therapies has been particularly challenging; becaus
95 In response to dideoxy inosine/hydroxyurea dual therapy, HIV-1 (human immunodeficiency virus type-1
96 Patients were classified as having received dual therapy if IV metronidazole was given within the sa
97 Patients were classified as having received dual therapy if IV metronidazole was given within the sa
100 to 55%) with TH (P = .13), with no effect of dual therapy in the hormone receptor-positive subset but
101 10 mg prednisone daily, and any advantage of dual therapy in the prevention of disease reactivation w
102 ubset but a significant increase in pCR with dual therapy in those with hormone receptor-negative dis
103 for the use of triple therapy compared with dual therapy in treatment of both naive individuals and
104 %) of 932 patients (annualised rate 2.2%) on dual therapy including cilostazol and 64 (7%) of 947 pat
105 D, and SH among patients with T2DM on Met-SU dual therapy intensified with DPP4i, insulin, or TZD.
109 s confirm that T(RM) establishment following dual therapy is associated with tumor remission in a sub
113 scalation-to-combination cohort increased to dual therapy, most commonly PDE5i + ERA (39.4%) and PDE5
115 riple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.00
116 Systematic reviews and randomized trials of dual therapy or monotherapy with 1 or more of the preced
118 Patients were randomly assigned (1:1) to dual therapy or triple therapy by sealed envelopes, in b
119 tions between any drug class as monotherapy, dual therapy, or triple therapy with odds of cardiovascu
120 ording to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral me
121 reduction in the primary end point: 43.8% of dual-therapy patients were MES positive on day 7, as com
125 to incorporate phage and antibiotics into a dual therapy regimen; however, this increases the comple
127 rs Paneth-like plasticity to drive KRAS-EGFR dual therapy resistance in CRC and highlight FGFR3 block
129 This study compared 1-year TLF in BES vs dual therapy sirolimus-eluting Combo stent (DTS) in an a
131 to systemic prostate issues, implementing a dual-therapy strategy that addresses both the local infl
133 ed the role of metformin as a monotherapy or dual therapy supplement and found significant benefit wh
134 at, for patients with T2DM who are on Met-SU dual therapy, the addition of DPP4i was a preferred thir
135 We did not find a difference between mono or dual therapy treatment for mortality, decompensation, or
140 1 year, high-certainty evidence showed that dual therapy was associated with reduced risk for major
143 ute noncardioembolic ischemic stroke or TIA, dual therapy was more effective than monotherapy in redu
144 ainty evidence showed that triple therapy vs dual therapy was significantly associated with a reducti
145 severe asthma, triple therapy, compared with dual therapy, was significantly associated with fewer se
147 with triple therapy than with monotherapy or dual therapy, whereas there was no difference between mo
148 modeling demonstrate why targeted mono- and dual therapies will likely fail in sufficiently large ca
149 med to compare the efficacy and safety of VA dual therapy with 2 g amoxicillin or 3 g amoxicillin, an
150 tibacterial activity of this macrolide since dual therapy with ampicillin and azithromycin against an
153 late compared with 5.4% (9 of 167) receiving dual therapy with anti-cytotoxic T-lymphocyte-associated
154 relation between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical o
155 ol and Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonor
156 idence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly bu
157 to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine com
159 Pilot studies are evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC
160 ations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GF
161 for pharyngeal gonorrhea treatment recommend dual therapy with intramuscular ceftriaxone and either a
166 inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dy
170 ansplant recipients can be safely reduced to dual therapy with MMF or CNIs, applying concentration-co
174 only 8 percentage points less effective) as dual therapy with PHMB 0.02%+ propamidine (a widely used
175 After treatment with ceftriaxone mono- or dual therapy (with azithromycin or doxycycline), anal, v
176 Is, and being on dolutegravir monotherapy or dual therapy, with rates higher in children than in adul